相关实验视频

Updated: Jan 7, 2026

Bile Salt-induced Biofilm Formation in Enteric Pathogens: Techniques for Identification and Quantification

Bile Salt-induced Biofilm Formation in Enteric Pathogens: Techniques for Identification and Quantification

Published on: May 6, 2018

血胆酸剖析揭示了儿科败血症早期诊断生物标志物的新发现

Lipeng Zhang^1,2,3, Jing Liu¹, Yuanmei Chen¹

¹Department of Pediatrics, China-Japan Friendship Hospital, Beijing, People's Republic of China.

Journal of inflammation research

|January 1, 2026

概括

胆酸分析对早期儿科败血症诊断有希望. 特定的胆酸如UDCA,GUDCA,GCA和DCA可以预测败血症,帮助及时干预和改善患者的结果.

科学领域:

代谢学代谢学代谢学
生物标志物发现发现
儿科败血症研究研究

背景情况:

败血症的诊断是具有挑战性的,需要新的生物标志物用于早期检测.
胆酸 (BAs) 与各种疾病有关,但它们在败血症中的作用需要进一步调查.
儿科败血症存在独特的诊断障碍,强调需要特定的生物标志物.

研究的目的:

为了确定与败血症相关的代谢物.
评估胆汁酸作为儿科败血症的潜在早期诊断和预后生物标志物.
为了探索胆汁酸途径在败血症中的失调.

主要方法:

采用非向的LC-MS代谢学来进行差异化代谢物识别.
对12种血胆酸进行了有针对性的定量分析.
使用机器学习算法 (RFE,LASSO,RF,SVM-RFE,GBDT) 来识别关键的BA预测器.

主要成果:

在败血症患者中确定了初级和二级胆酸的显著变化.
机器学习模型将UDCA,GUDCA,GCA和DCA确定为败血症诊断的关键预测因素 (AUC=0.880).
特定胆酸比率 (DCA/CA,GCDCA) 预测了败血症休克,而LCA预测了呼吸衰竭.

结论:

胆酸分析具有作为儿科败血症的诊断和预后工具的潜力.
这些发现支持基于胆酸生物标志物的早期干预策略的开发.
及时检测和以胆酸概况为指导的治疗可以改善患者的治疗结果.

关键词:

这就是LC-MS.胆汁酸胆汁酸胆汁酸生物标志物生物标志物液体染色学-质谱学-质谱学代谢生物组的代谢生物组儿科儿科儿科这是一种血症.

更多相关视频

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport

Published on: November 27, 2016

Evaluation of a Reliable Biomarker in a Cecal Ligation and Puncture-Induced Mouse Model of Sepsis

Evaluation of a Reliable Biomarker in a Cecal Ligation and Puncture-Induced Mouse Model of Sepsis

Published on: December 9, 2022

相关概念视频

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...

Pharmacokinetics in Pediatric Patients: Drug Metabolism

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...